UnknownPhase 1NCT04934774

Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell Malignances

Studying Acute lymphoblastic leukemia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
iCell Gene Therapeutics
Principal Investigator
Hongyu Zhang
Peking University Shenzhen Hospital, China
Intervention
CD7 CAR T cells(biological)
Enrollment
20 enrolled
Eligibility
18 years · All sexes
Timeline
20202023

Study locations (1)

Collaborators

iCAR Bio Therapeutics Ltd. · Peking University Shenzhen Hospital

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04934774 on ClinicalTrials.gov

Other trials for Acute lymphoblastic leukemia

Additional recruiting or active studies for the same condition.

See all trials for Acute lymphoblastic leukemia

← Back to all trials